Shereen Elazzazy
Doha, DA, Qatar
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study).
Journal: Frontiers in immunology
Published: June 07, 2026
Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region.
Journal: Expert review of anticancer therapy
Published: May 06, 2026
CLO26-124: Comparative Outcomes of CDK4/6 Inhibitors and Endocrine Therapy in HER2-Low Versus HER2-Negative Metastatic Breast Cancer: A Retrospective Nationwide Cohort Study From Qatar.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026
Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.
Journal: Journal of pharmaceutical policy and practice
Published: February 23, 2026
Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study).
Journal: Frontiers in immunology
Published: July 14, 2025
Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis.
Journal: Clinical drug investigation
Published: November 21, 2024
Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation.
Journal: Frontiers in oncology
Published: April 07, 2024
Establishment of a clinical pharmacist-led multiple myeloma clinic with collaborative prescribing model at the national center for cancer care and research in Qatar.
Journal: Journal of the American Pharmacists Association : JAPhA
Published: March 26, 2024
HER2-low non-metastatic breast cancer in Qatar-a nationwide retrospective cohort study to evaluate the response to neoadjuvant chemotherapy: a real-world analysis.
Journal: Frontiers in oncology
Published: March 08, 2024
Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study.
Journal: Clinical Medicine Insights. Oncology
Published: January 14, 2024
The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study.
Journal: Frontiers in oncology
Published: April 11, 2023
Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation.
Journal: International journal of environmental research and public health
Published: October 11, 2022
Last Updated: 09/26/2026